We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00213031
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : August 14, 2017
Information provided by:

Study Description
Brief Summary:

The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months. Secondary aims were to gather preliminary data on Carraguard's effectiveness in preventing male-to-female transmission of HIV, and other STIs.

The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women would find Carraguard acceptable. The study was not powered to determine effectiveness, but based on safety, acceptability and feasibility parameters, the outcome of the Phase 2 trial would enable a decision whether or not to proceed to a Phase 3 trial.

Condition or disease Intervention/treatment Phase
HIV Infections Chlamydia Trachomatis Neisseria Gonorrhoeae Trichomonas Vaginitis Syphilis Herpes Simplex Drug: Carraguard (PC-515) Phase 2

Detailed Description:

Carraguard™ (PC-515), the Population Council's lead candidate microbicide, was tested in a triple-masked, randomized, placebo-controlled trial fielded in one site in Chiang Rai, northern Thailand. The primary aims of the study were to assess Carraguard's safety (toxicity) - including signs of local irritation, such as itching or burning; changes in vaginal flora; and incidence of abnormal external genital, vaginal, and cervical findings - when applied vaginally for 12 months; to evaluate acceptability; to assess feasibility of conducting a large scale microbicide trial in a non-sex worker population; to gauge women's reactions to a non-contraceptive microbicide; and to explore microbicide use dynamics in a Thai population.

Secondary aims were to investigate HIV infections averted (preliminary indications); other sexually transmitted infections averted - including C. trachomatis, N. gonorrhoeae, T. vaginalis, and T. pallidum (preliminary indications); and effect on cervical cytology.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Other
Official Title: A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of PC-515 (Lambda Carrageenan) for Vaginal Use as a Possible Microbicide
Actual Study Start Date : February 2000
Study Completion Date : December 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Safety: Genital exam & interview for symptoms after 14 days & monthly thereafter; colposcopy done throughout trial at clinicians' discretion; monthly testing to detect changes in vagina flora.
  2. Compliance: collection of applicators and interview(monthly)
  3. Acceptability: interview (quarterly)

Secondary Outcome Measures :
  1. Preliminary effectiveness: Swabs taken to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis and for genital ulcer disease, if ulceration was detected; blood drawn for syphilis and HIV testing and for HSV-2 Pap smear to det

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • In good health as determined by medical history, physical examination and results of laboratory screening tests
  • Aged 18 years or older
  • Resident in the area for at least one year and planning to stay for at least 12 months
  • HIV-seronegative at baseline
  • Willing and able to comply with the study protocol (including being tested for HIV, learning the results, and undergoing clinical evaluations)
  • Able to achieve a score of 80% or better on true-false test of key study concepts
  • Able to give informed consent

Exclusion Criteria:

  • Pregnant or desire to become pregnant at time of study participation
  • Delivered or aborted a pregnancy within the six weeks prior to screening
  • Male sex partner known at enrollment to be HIV positive
  • History of surgery on external genitalia, vagina or cervix in the six weeks prior to screening
  • Recent history of non-menstrual vaginal bleeding with intercourse
  • Clinically detectable genital abnormality (including presence of warts, or a structural or congenital abnormality)
  • Clinical suspicion of a reproductive tract infection (RTI), defined as the presence of a genital ulcer visible to the naked eye, an abnormal vaginal discharge or purulent cervicitis, or untreated positive STD result (Women could be enrolled after treatment of identified RTI. Women with persistent genital epithelial disruption, i.e., ulcer, abrasion or fissure, were not eligible.
  • Women with other persistent abnormal signs, such as vaginal or cervical discharge, despite treatment of identified RTI, were eligible)
  • Abnormal Pap smear (Class II or above)
  • History of sensitivity/allergy to latex
  • Concurrent participation in another trial of a vaginal product
  • Injection of recreational drugs
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00213031

Chiang Rai Health Club
Chiang Rai, Thailand, 57001
Sponsors and Collaborators
Population Council
Bill and Melinda Gates Foundation
Centers for Disease Control and Prevention
Nat'l Cntr. for HIV, STD, & TB Prevention Atlanta: Division of STD Prevention,Div. of HIV/AIDS Prevention—Surveillance & Epidemiology
National Center for Infectious Diseases
Ministry of Health, Thailand
Collaboration (TUC)
Chiang Rai Public Health Office
Chiang Rai District Health Office
Chiang Rai Municipal Health Office
Chiang Rai Hospital
Principal Investigator: Janneke HMM van de Wijgert, Ph.D. Population Council
More Information

ClinicalTrials.gov Identifier: NCT00213031     History of Changes
Other Study ID Numbers: Population Council #271
CDC & Prevention #2485
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: August 14, 2017
Last Verified: August 2017

Keywords provided by Population Council:
HIV prevention
sexually transmitted infections
female-initiated protection
expanded safety trial
HIV Seronegativity

Additional relevant MeSH terms:
HIV Infections
Herpes Simplex
Trichomonas Infections
Trichomonas Vaginitis
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Herpesviridae Infections
DNA Virus Infections
Skin Diseases, Viral
Skin Diseases, Infectious
Skin Diseases
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Genital Diseases, Male
Genital Diseases, Female
Vaginal Diseases
Treponemal Infections
Spirochaetales Infections